Technical Analysis for IMVT - Immunovant, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 30.27 | -0.85% | -0.26 |
IMVT closed down 0.85 percent on Monday, March 18, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Resistance | Bearish | 0.00% | |
New Downtrend | Bearish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Multiple of Ten Bullish | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 200 DMA | Bearish | -0.85% |
Alert | Time |
---|---|
Possible NR7 | about 16 hours ago |
Rose Above 200 DMA | about 16 hours ago |
200 DMA Resistance | about 19 hours ago |
60 Minute Opening Range Breakout | about 19 hours ago |
Fell Below Previous Day's Low | about 20 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/01/2024
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immune System Eye Autoimmune Disease Antibodies Monoclonal Antibodies Monoclonal Antibody Anemia Thyroid Eye Diseases Treatment Of Autoimmune Disease Myasthenia Gravis Transfusion Medicine Myasthenia Thyroid Eye Disease Acquired Hemolytic Anemia Treatment Of Myasthenia Gravis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immune System Eye Autoimmune Disease Antibodies Monoclonal Antibodies Monoclonal Antibody Anemia Thyroid Eye Diseases Treatment Of Autoimmune Disease Myasthenia Gravis Transfusion Medicine Myasthenia Thyroid Eye Disease Acquired Hemolytic Anemia Treatment Of Myasthenia Gravis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 45.58 |
52 Week Low | 14.05 |
Average Volume | 1,239,277 |
200-Day Moving Average | 30.70 |
50-Day Moving Average | 37.02 |
20-Day Moving Average | 34.22 |
10-Day Moving Average | 31.79 |
Average True Range | 1.65 |
RSI (14) | 26.47 |
ADX | 25.22 |
+DI | 10.67 |
-DI | 28.65 |
Chandelier Exit (Long, 3 ATRs) | 34.59 |
Chandelier Exit (Short, 3 ATRs) | 34.67 |
Upper Bollinger Bands | 39.61 |
Lower Bollinger Band | 28.84 |
Percent B (%b) | 0.13 |
BandWidth | 31.46 |
MACD Line | -1.85 |
MACD Signal Line | -1.50 |
MACD Histogram | -0.3436 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 31.50 | ||||
Resistance 3 (R3) | 31.54 | 31.18 | 31.30 | ||
Resistance 2 (R2) | 31.18 | 30.86 | 31.16 | 31.23 | |
Resistance 1 (R1) | 30.72 | 30.67 | 30.54 | 30.68 | 31.16 |
Pivot Point | 30.36 | 30.36 | 30.27 | 30.34 | 30.36 |
Support 1 (S1) | 29.90 | 30.04 | 29.72 | 29.86 | 29.38 |
Support 2 (S2) | 29.54 | 29.85 | 29.52 | 29.31 | |
Support 3 (S3) | 29.08 | 29.54 | 29.25 | ||
Support 4 (S4) | 29.04 |